Screening of tumor mark for the lung cancer by using peptide ZS-6 / 中国药理学通报

Aim To select a potential biomarker for early lung cancer diagnosis and targeted therapy by using the cancer specific bounded peptide ZS-6 which had already been obtained from the laboratory.Methods The peptide ZS-6 marked by biotin was used as a probe to pan out the human lung cancer cDNA phage display library,after 4 rounds of subtraction panning,the specific binding clones of ZS-6 were identified.After amplification and purification,then those DNA sequences were identified and analyzed with bioinformatics.Results 18 phage clones were identified to the specific peptide ZS-6 and the DNA sequence showed one of them was an unknown new gene while the others were known tumor related genes.Conclusion A tumor biomarker selected from human lung cancer cDNA library provides a potential tool for early lung cancer diagnosis and therapy.

Screening and preliminary identification of liver cancer specific peptide from a phage display peptide library / 中华肝胆外科杂志

Objective To obtain short peptides which specifically binds to HepG2 cell line from 12 peptide libraries, and lay foundation for screening and identifying the new liver cancer markers for early diagnosis and treatment of liver cancer. Methods The liver cancer cell line HepG2 was used as the antigen and LO-2 as the absorber cells for subtraction biopanning from a phage display peptide library at 37℃. The positive phage clones were identified by cell enzyme-linked immunosorbentassay (EL1SA), and the identity of DNA sequence and amino acids were analyzed. Results After 3 rounds of screening, 30 phage clones were identified by EL1SA, ZS-9 of them bind to the HepG2 specifically. The amino acid sequence was blast in NCBI and Swiss-Prot, the results show that the sequence has not identity with the known genes and proteins in the database, and the sequence was not reported in literature. All these show that we had discovered several novel liver cancer associated antigen ligand. Conclusion Several candidate peptide binding to liver cancer specifically have been selected by phage display technology, providing the potential uses for early diagnosis of liver cancer or targeted therapy for liver cancer.